Watch this on-demand webcast, Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD, for an expert panel discussion on the science behind cytokine-targeting therapies and how to use this information to individualize and improve treatment decisions for your patients with IBD.
Recently, interleukin (IL)-23 and the inflammatory IL-23/T-helper (Th)-17 axis have been identified as central drivers of inflammation related to inflammatory bowel disease (IBD). Science in the field of cytokine-targeting therapies, specifically in the field of IL-23 P19 targeting agents, is evolving rapidly. The first approval in the class occurred in 2022 and several other agents in late-stage development. While all agents within the anti-IL-23 class will have the ability to bind to and neutralize IL-23 via binding to the P19 domain as an essential function, structural differences in the monoclonal antibody Fc fragment result in each agent having an overall unique clinical profile.
During this presentation, our speakers will utilize animated 3-D models to discuss therapeutic mechanisms of action of emerging agents, clinical distinctions between therapies, and individualizing treatments for lasting outcomes for patients with IBD. This webcast was developed by CME Outfitters and is accredited by AGA.
Learning Objectives:
- Assess the role of various pro-inflammatory cytokines to inflammation in the pathogenesis of IBD.
- Classify the role of the IL-23 and Th17 pathway in IBD pathogenesis.
- Evaluate the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in the treatment of IBD.
Faculty and Webinar Panelists:
Maria T. Abreu, MD, AGAF
Professor of Medicine
Professor of Microbiology and Immunology
Director, Crohn’s and Colitis Center
University of Miami Miller School of Medicine
President-Elect, AGA
Miami, FL
Jessica R. Allegretti, MD, MPH, AGAF
Director, Crohn’s and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, MA
David T. Rubin, MD, AGAF
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
Disclosures
Dr. Dubinsky reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; Prometheus Laboratories; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Ali reports the following financial relationships:
Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Consultant: AbbVie Inc.; Boehringer Ingelheim; E.R. Squibb & Sons, L.L.C.; and Fresenius Kabi USA
Research Support: AbbVie Inc.; Arena Pharmaceuticals; AstraZeneca; and Celgene Corporation
Speakers Bureau: AbbVie Inc.; E.R. Squibb & Sons, L.L.C.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Long reports the following financial relationships:
Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE
Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Sept. 29, 2024
Sponsor:
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.